Cross‐reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A
Authors:
- 30 September 2020
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 26 (6) , 1181-1186
Abstract
Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of autoantibodies to endogenous human factor VIII (hFVIII). If treatment of bleeding is required, one option is recombinant porcine FVIII (rpFVIII). Cross‐reactivity between factor VIII inhibitors and rpFVIII has previously been described. Aim The aim of this study was to retrospectively assess the incidence of cross‐reacting anti‐porcine inhibitors in patients diagnosed with AHA in two UK centres. Methods The plasma of fifty‐one patients diagnosed with AHA via reduced FVIII:C and positive FVIII inhibitor titre as detected with a Nijmegen‐Bethesda assay (NBA) was also tested by a porcine Bethesda assay (PBA). The NBA was modified by replacement of human FVIII with rpFVIII in the PBA, with determination of residual FVIII by one‐stage clotting assay. Results The median FVIII inhibitor titre by NBA was 22.8 BU/mL (range: 0.8‐1000 BU/mL). 37% of samples exhibited linear, type 1 kinetics in the NBA. Negative PBA was observed in 26 patients, and 25 were positive (median PBA: 3.5 BU/mL; range: 0.8‐120 BU/mL). Type 1 kinetics were observed in 40% of PBA‐positive patients. At NBA tires of greater than 100 BU/mL, the positive predictive value for the presence of porcine cross‐reactivity was 100%. At NBA below 5 BU/mL, the negative predictive value for the presence of porcine cross‐reactivity was 71%. Conclusion Cross‐reactivity between FVIII inhibitors and rpFVIII was observed in 49% of patients. The presence of inhibitors to rpFVIII may influence the treatment choice for patients with acquired haemophilia A.Keywords
This publication has 22 references indexed in Scilit:
- Epitope mapping via selection of anti-FVIII antibody-specific phagepresented peptide ligands that mimic the antibody binding sitesThrombosis and Haemostasis, 2015
- Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humansBlood, 2015
- Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDOBritish Journal of Haematology, 2013
- Acquired haemophilia A: A 2013 updateThrombosis and Haemostasis, 2013
- Pregnancy‐associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registryBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIIIJournal of Thrombosis and Haemostasis, 2012
- Validation of Nijmegen–Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillanceJournal of Thrombosis and Haemostasis, 2012
- The comparative immunogenicity of human and porcine factor VIII in haemophilia A miceThrombosis and Haemostasis, 2009
- Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' OrganisationBlood, 2006
- Acquired hemophilia A: A concise reviewAmerican Journal of Hematology, 2005